Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agents.

@article{Hoff1977WhateverHT,
  title={Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agents.},
  author={Daniel D. Von Hoff and Marcel Rozencweig and William D. Soper and Lee J. Helman and John S. Penta and Hugh L. Davis and Franco M. Muggia},
  journal={Cancer treatment reports},
  year={1977},
  volume={61 5},
  pages={
          759-68
        }
}
Twenty-six investigational anticancer drugs formerly supplied by the National Cancer Institute are no longer available due to the lack of requests for their use in clinical trials. This report examines the data on these drugs to determine how well they were clinically evaluated. Generally, the studies are incomplete, and 34% of the compounds have not been studied beyond phase I trials. Clinical pharmacology data were not obtained for most of the drugs. In addition, the information available for… CONTINUE READING